Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

SciSparc Ltd. SPRC NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • IL • USD

SharesGrow Score
31/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

SciSparc Ltd. (SPRC) is a Biotechnology company in the Healthcare sector, currently trading at $3.39. It has a SharesGrow Score of 29/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Valuation: SPRC trades at a trailing Price-to-Earnings (P/E) of -0 (S&P 500 average ~25).

Financials: revenue is $1M, +28.4%/yr average growth. Net income is $6M (loss), growing at -21.7%/yr. Net profit margin is -481.2% (negative). Gross margin is 38.7% (-58.2 pp trend).

Balance sheet: total debt is $46,000 against $8M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 5.36 (strong liquidity). Debt-to-assets is 0.4%. Total assets: $10M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 21/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

SPRC SharesGrow Score Overview

39/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 21/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SPRC

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
SPRC: +28.4%/yr revenue is, -21.7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet SPRC: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 5.36 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
21/100
SPRC: Gross margin is 38.7% (-58.2 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 21/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
SPRC: Net profit margin is -481.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range3.37-94.5
Volume7.78K
Avg Volume (30D)100.02K
Market Cap$196.07K
Beta (1Y)1.33
Share Statistics
EPS (TTM)-1.08
Shares Outstanding$5.82M
IPO Date2021-08-30
Employees2
CEOOz Adler
Financial Highlights & Ratios
Revenue (TTM)$1.31M
Gross Profit$506K
EBITDA$-6.97M
Net Income$-6.28M
Operating Income$-7.32M
Total Cash$2.06M
Total Debt$46K
Net Debt$-1.49M
Total Assets$10.35M
Price / Earnings (P/E)-3.1
Price / Sales (P/S)0.15
Analyst Forecast
Company Info
CountryIL
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINIL0010951403

Price Chart

Track all markets on TradingView
SPRC
SciSparc Ltd. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
3.37 52WK RANGE 94.50

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.82
-0.72%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.56
+0.44%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.81
+1.26%
 YS
YS
YS Biopharma Co., Ltd.
$1.02
+9.68%
 UNCY
UNCY
Unicycive Therapeutics, Inc.
$6.97
+0.43%
 TIL
TIL
Instil Bio, Inc.
$8.89
+5.33%
 CVKD
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$4.81
+0.42%
 KPRX
KPRX
Kiora Pharmaceuticals, Inc.
$2.54
+4.10%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message